UK National Institute for Health and Care Excellence (NICE) Updates Endobronchial Valve Treatment Guidance to Standard Care
REDWOOD CITY, Calif. – December 20, 2017 – Pulmonx® Corp. today announced that the UK’s National Institute for Health and Care Excellence (NICE) has updated its guidance for endobronchial valves used to treat severe emphysema, an advanced form of chronic obstructive pulmonary disease (COPD), and now…
New Study Demonstrates Zephyr Endobronchial Valves Significantly Improve Breathing, Mobility and Quality of Life for Emphysema Patients
REDWOOD CITY, Calif. – September 8, 2017 – Pulmonx® Corp. today announced the publication of positive six-month results from TRANSFORM, a multicenter, multinational, randomized clinical trial (RCT) of the Zephyr® Endobronchial Valve (EBV®) in the American Journal of Respiratory and Critical Care…
New Data from Two Multi-Center Randomized Clinical Trials Demonstrate That Zephyr Endobronchial Valves Deliver Benefit to Both Heterogeneous and Homogenous Emphysema Patients without Collateral Ventilation
Washington DC and Redwood City, Calif. – May 23, 2017 – Pulmonx, Inc. today announced the results of two multi-center, randomized clinical trials showing clinically meaningful improvements in lung function after treatment with the Zephyr® Endobronchial Valve (EBV) in emphysema patients without…
GOLD Treatment Recommendations for COPD Now Include Use of Endobronchial Valves to Treat Patients with Emphysema
Redwood City, Calif. – November 18, 2016 – The Global Initiative for Chronic Obstructive Lung Disease (GOLD) issued a substantial revision to its COPD management recommendations that now includes bronchoscopic lung volume reduction with endobronchial valves as a treatment option for patients with…
Pulmonx Completes Enrollment in U.S. Pivotal Trial of Zephyr®Endobronchial Valve
Redwood City, Calif. – October 5, 2016 – Pulmonx, a leader in interventional pulmonology, today announced completion of enrollment in its pivotal IDE study – the LIBERATE Trial – a randomized, controlled, multi-center study of the Zephyr® Endobronchial Valve (EBV) in patients with severe emphysema,…
New Study Demonstrates Benefits of Pulmonx Zephyr®Endobronchial Valve in Patients with Homogeneous Emphysema
Results Published in American Journal of Respiratory and Critical Care Medicine Show Meaningful Improvements in Patient Lung Function, Exercise Tolerance and Quality of Life
New StratX Lung Analysis Platform from Pulmonx Enables Confident and Rapid Patient Selection for Zephyr® Endobronchial Valve Treatment
Cloud-Based Quantitative Computed Tomography (QCT) Analysis Service is Now Commercially Available
Zephyr Valves on TV – Emphysema patients in Adelaide
A new procedure is being used to improve breathing and quality of life for patients in Adelaide
Zephyr Valves on TV – Rocker Eddie Boekelman shares his story
“I got to the point where I just could not breathe anymore …”
STELVIO Trial Shows Sustained Benefits for Emphysema Patients One Year After Treatment with Zephyr® Endobronchial Valves
Redwood City, Calif. – May 18, 2016 – Pulmonx®, a leader in interventional pulmonology, today announced positive one year results from the groundbreaking STELVIO trial. The STELVIO trial is the first randomized controlled study of Zephyr® Endobronchial Valves (EBV) in severe emphysema patients…